May 21, 2016
Novartis’ Entresto® (sacubitril/valsartan) has been given a Class I recommendation, the strongest endorsement, in updated clinical practice guidelines simultaneously released by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU.
Entresto is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) in the US as an alternative to an angiotensin II receptor blocker or an ACE inhibitor, given together with a beta blocker and an aldosterone antagonist. Furthermore, the guidelines call for doctors to switch HFrEF patients with mild to moderate symptoms from ARBs or ACEs to Entresto.
“These strong, swift and broad recommendations by US cardiology organizations, redefine the standard of care for how reduced ejection fraction heart failure is treated. We know patients with heart failure suffer reduced quality of life and remain at high risk of hospitalization or death, and these new guidelines are a strong call to action to ensure patients receive the most effective therapies,” said Vas Narasimhan, Global Head of Development and Chief Medical Officer for Novartis. “Entresto® of Novartis given strong Class I recommendation for the Treatment of Heart Failure in both US and EUlast edit: 2016-05-30T16:23:17+00:00da